VYNE Therapeutics Inc. Share Price & Technical Analysis
VYNE · $0.67 (-1.47%)
Healthcare / Biotechnology
$0.67
-1.47%
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pat…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
17% return in May, -4% avg return in past 3 year May month.
17% return in 2026, 22% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 0% | 0% | 17% | – | – | – | – | – | – | – | 17% |
| 25 | -32% | 9% | -36% | -19% | -31% | 60% | -75% | 0% | 0% | 33% | 0% | 50% | -41% |
| 24 | -29% | 29% | 41% | -19% | 0% | -23% | -5% | -5% | 6% | 42% | 11% | 14% | 61% |
| 23 | 74% | -33% | -6% | 77% | 19% | -34% | 18% | -10% | -11% | -23% | 10% | -34% | 46% |
| 22 | -39% | -12% | 18% | -39% | -6% | -3% | 1% | -25% | -30% | 15% | -12% | -36% | -168% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$22.38M
P/E ratio
—
52W high
$1.96
52W low
$0.28
Volume
78,516
Beta
2.00
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is VYNE Therapeutics Inc. share price today?
- VYNE Therapeutics Inc. (VYNE) last traded around $0.67 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VYNE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VYNE. Download the app for real-time alerts.
- How can I analyze VYNE Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.